4 HealthTech Stocks Trending Now MLTX stock, BMRN stock, MRNA stock, AZNCF stock
Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at finmarketnews.com, will continue to monitor these healthtech companies to see if the momentum continues. FinMarketNews.com is looking into these tickers DAWN, MTDR, AVY, CMC, MNST, RTX and more..
Recent MLTX Stock Price: $57.40
Summary: MoonLake Immunotherapeutics AG is a clinical-stage biotechnology company. It focused on creating next-level therapies for inflammatory skin and joint diseases. MoonLake Immunotherapeutics AG, formerly known as Helix Acquisition Corp., is based in BOSTON.
Alex Cogut analyst at Bryan Garnier & Co Ltd reiterates coverage on MoonLake Immunotherapeutics (MLTX) stock in the energy sector with a Hold rating and has set MLTX's stock price target at $60.
TipRanks.com reports that MoonLake Immunotherapeutics currently has 5 analysts offering 12-month price targets on MLTX and the consensus is a Strong Buy rating with an average stock price target of $71.80. The most recent MLTX stock price we have is $57.40 and we are not making any MLTX forecasts at this time.
In addition, TradingView issued a buy rating for MLTX over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on MLTX. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on MLTX, please click here >>
BioMarin Pharmaceutical, BMRN
Recent BMRN Stock Price: $87.68
Summary: BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder), Vimizim , Brineura, Palynziq and Voxzogo. BioMarin has a collaboration agreement with Sanofi's subsidiary Genzyme for Aldurazyme. Genzyme is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.'The newest drug in BioMarin's portfolio, Voxzogo for treating achondroplasia, the most common form of dwarfism. BioMarin's biologics license application (BLA) for Roctavian/valoctocogene roxaparvovec (valrox), a gene therapy for severe hemophilia A, was given a complete response letter (CRL) by the FDA.
Andreas Argyrides analyst at Wedbush reiterates coverage on BioMarin Pharmaceutical (BMRN) stock in the energy sector with a Hold rating and has set BMRN's stock price target at $78.
TipRanks.com reports that BioMarin Pharmaceutical currently has 4 analysts offering 12-month price targets on BMRN and the consensus is a Moderate Buy rating with an average stock price target of $99.50. The most recent BMRN stock price we have is $87.68 and we are not making any BMRN forecasts at this time.
In addition, TradingView issued a Strong sell rating for BMRN over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on BMRN. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on BMRN, please click here >>
Moderna, MRNA
Recent MRNA Stock Price: $112.81
Summary: Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency use in several countries as COVID-19 vaccine. The company has also developed booster doses of its COVID-19 vaccine and is developing variant-specific booster candidates.
Terence Flynn analyst at Morgan Stanley reiterates coverage on Moderna (MRNA) stock in the energy sector with a Hold rating and has set MRNA's stock price target at $123.
TipRanks.com reports that Moderna currently has 5 analysts offering 12-month price targets on MRNA and the consensus is a Moderate Buy rating with an average stock price target of $159.60. The most recent MRNA stock price we have is $112.81 and we are not making any MRNA forecasts at this time.
In addition, TradingView issued a buy rating for MRNA over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on MRNA. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on MRNA, please click here >>
AstraZeneca, AZNCF
Recent AZNCF Stock Price: $133.00
Summary: AstraZeneca PLC was incorporated in England and Wales on 17 June 1992. From February 1993 until April 1999, the Company was called Zeneca Group PLC. On 6 April 1999, the Company changed its name to AstraZeneca PLC. It is a biopharmaceutical company. The Company focuses on three important areas of healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). The Company is also engaged in the Infection, Neuroscience and Gastrointestinal (ING) disease areas. It operates in more than 100 countries.
Sachin Jain analyst at Bank of America Securities reiterates coverage on AstraZeneca (AZNCF) stock in the energy sector with a Buy rating and has set AZNCF's stock price target at $196.63.
TipRanks.com reports that AstraZeneca currently has 5 analysts offering 12-month price targets on AZNCF and the consensus is a Moderate Buy rating with an average stock price target of $173.40. The most recent AZNCF stock price we have is $133.00 and we are not making any AZNCF forecasts at this time.
In addition, TradingView issued a sell rating for AZNCF over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on AZNCF. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on AZNCF, please click here >>
The editors at finmarketnews.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
FinMarketNews.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to FinMarketNews.com.
==============================================================================